Providing Scientific Stewardship to the Healthcare Industry and Counsel.
The ToxicoGenomica team has brought genomic causation analysis into over 30 cancer cases for defendants in cases involving benzene, radiation, and asbestos (see here for a description of five of the older cases). Read more
Innovative Science Solutions has been closely following the peer-reviewed scientific literature related to COVID-19. Read more
A valuable web site illustrates the power and speed of using virus genomes to track and understand the global spread of #Covid19. Read more
On October 16th, 2019, the Antimicrobial Drugs Advisory Committee (AMDAC) reviewed. Read more
The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) met on November 14th to review. Read more
The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) met on November 13th to discuss the Boehringer Ingelheim Pharmaceuticals. Read more
This article was co-authored by Steve J. Bannister, PhD, of Hightower Pharmaceutical Services. He has over thirty years of experience applying the fundamentals of physical and analytical chemistry to development of drug-delivery devices. Read more
The Arthritis Advisory Committee (AAC) met on July 25th to review the supplemental New Drug Application. Read more
On September 9-11, Dr. Len van Zyl of ToxicoGenomica will be speaking at Perrin Conferences’ National Asbestos Litigation Conference at the Fairmont San Francisco Hotel, San Francisco, CA. Read more
On February 26th, 2019, the Oncologic Drugs Advisory Committee assembled to determine the fate of Karyopharm Therapeutics’ latest drug. Read more
E-cigarettes and other reduced risk nicotine products (such as smokeless tobacco, heated tobacco, and tobacco-free nicotine products) have generated enormous interest across a spectrum of stakeholders, including smokers who have reportedly quit smoking using one or more of these new (potentially) reduced risk products. Read more
On May 8th, 2019 the Pulmonary-Allergy Drugs Advisory Committee (PADAC) convened to review the new drug application (NDA) Read more
The Oncologic Drugs Advisory Committee (ODAC) reviewed the new drug application (NDA) #211810. Read more
On February 12th, 2019, Janssen Pharmaceuticals, Inc. discussed their New Drug Application (NDA) #211243. Read more
In a recently published article, Pizzurro and colleagues report several important interspecies differences in perfluoroalkyl substances (PFAS) toxicokinetics. Read more
Per- and polyfluoroalkyl substances (PFAS) are a diverse group of chemical compounds that resist degradation in the environment. Read more
On May 6, 2019, a study published in the Journal of the American Medical Association reported that several sunscreens used under maximal conditions resulted in plasma concentrations of active ingredients that exceeded the threshold limit established by the U.S. Food and Drug Administration (FDA). Read more
On January 11th, 2019, Takeda Pharmaceuticals appeared before a joint session of the Arthritis Advisory and the Drug Safety and Risk Management Advisory Committees. Read more